Compare Ryanair Holdings plc (RYAAY) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ryanair Holdings plc vs Smith & Nephew plc — how do they compare? Ryanair Holdings plc trades at $54.24 (market cap $27.11B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Ryanair Holdings plc is far larger — about 2.4× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Ryanair Holdings plc for 72 Days and Smith & Nephew plc for 121 Days on average.
| RYAAY | SNN | |
|---|---|---|
Market Cap | $27.11B | $11.10B |
Volume | 2,427,380 | 1,051,703 |
Sector | Industrials | Health |
52-Week High | $73.82 | $37.17 |
52-Week Low | $51.95 | $26.42 |
Typical Hold Time | 72 Days | 121 Days |
Enterprise Value | $24.18B | $14.13B |
Dividend Yield | 1.66% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RYAAY trades at $54.04, down 3.5% on the day, with a bearish technical signal from moving averages. The company reported revenue of $13.95 billion in 2025 and net income of $1.61 billion, with a P/E ratio of 13.43. Recent earnings have been mixed, with a miss in Q2 2026. News highlights include CEO commentary on Boeing MAX 10 delays and concerns over fuel costs impacting future airfares.
The stock presents a valuation opportunity with low P/E and EV/EBITDA multiples, but faces near-term headwinds from volatile fuel prices and reduced traffic forecasts. Analyst consensus is moderately bullish, with 65% buy ratings, though technical indicators suggest caution. Key risks include oil price sensitivity and competitive pressures in the European airline sector.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
